Germany’s Drug Price Model: Would it Work in the U.S.?
In a recent post on the IVI-sponsored Health Affairs blog series, Karl Lauterbach, John McDonough, and Elizabeth Seely suggest that Germany’s AMNOG (the Act to Reorganize Pharmaceuticals Market in the Statutory Health Insurance System or Arzneimittelmarktneuordnungsgesetz) model should be applied to U.S. drug pricing policy. Read the full article here. About the Health Affairs/IVI Featured Blog Series: […]
Lakdawalla, Sachs, and Bagley Focus on Medicaid’s Best-Price Rule and Trump Administration Opportunity to Advance Value-Based Pricing
In a recent post on the IVI-sponsored Health Affairs featured blog series, IVI’s Executive Director, Darius Lakdawalla, along with Rachel Sachs and Nicholas Bagley, examine how Medicaid’s best-price rule complicates the development of value-based pricing and suggest a potential solution that could come out of the new Trump administration CMS policies. Read the full article here. About […]
FDA’s Scott Gottlieb and The Goldilocks Theory
In a recent post on the IVI-sponsored Health Affairs featured blog series, Ian Spatz outlines the challenges facing new FDA commissioner Scott Gottlieb. Among the challenges identified are the determination of new criteria for the control of medical information and the encouragement of competition to control drug costs. Read the full article here. About the Health Affairs/IVI Featured […]
Orphan Drugs, Pursuing Value, and Avoiding Unintended Effects of Regulations
In a recent post on the IVI-sponsored Health Affairs featured blog series, Joshua Liao and Mark Pauly examine the role of government regulation of orphan drugs in rising drug prices, providing some specific examples and how they relate to the provisions of the Orphan Drug Act. Liao and Pauly also present some potential solutions to the problem, including […]
Lakdawalla and Balch Make the Case for Patient-Centered Assessment of Value
In a recent post on the IVI-sponsored Health Affairs featured blog series, IVI’s Darius Lakdawalla and Alan Balch stress the importance of incorporating the patient perspective into value assessments in healthcare, and of developing tools to help patients make value-based decisions in the marketplace. The Balch and Lakdawalla piece reflects IVI’s view that value in healthcare rests […]
Hwang and Kesselheim Analyze the Impact of Taxing Drug Price Spikes
In a recent post on the IVI-sponsored Health Affairs featured blog series,Thomas Hwang and Aaron Kesselheim examine proposed new legislation taxing manufacturers of pharmaceuticals with medications exhibiting significant pricing spikes. Hwang and Kesselheim break down the criteria for the tax, and also offer some insight into potential policy implications. Read the full article here. About the Health […]
Review of Key Provisions of FDA’s User Fee Reauthorization Bill
In the latest post on the IVI-sponsored Health Affairs featured blog series, Rachel Sachs addresses key provisions of the FDA’s proposed user fee reauthorization bill. Included in her assessment are details of new language changes and amendments added to the bill, as well as a look forward to potential obstacles to the bill’s final passage. Read […]
Examining Policies to Promote Development of Antimicrobial Drugs
In the latest post on the IVI-sponsored Health Affairs featured blog series, Seth Seabury and Neeraj Sood examine the challenges to addressing the significant threat that antimicrobial resistant infections pose to human health. In their commentary, Seabury and Sood focus on three of the most commonly proposed policies to promote the development of new antimicrobials: market […]
What Matters Most to Patients
In a post on the IVI-sponsored Health Affairs blog series,Josh Seidman, Margaret Anderson, Domitilla Masi, Melea Atkins and Maureen Japha examine the role of patient perspectives in assessing value in healthcare, focusing on the Avalere-FasterCures Patient-Perspective Value Framework as an example of progress toward a more patient-centered approach to value assessment. Read the full article […]
Manolis, Good and Shrank Address Abuse-Deterrent Opioids
In the latest post on the IVI-sponsored Health Affairs blog series, Chronis Manolis, C. Bernie Good and William Shrank discuss current approaches to curbing rampant opioid abuse, including the mandating of coverage for abuse-deterrent opioids. The authors make the case that this tactic would be non-effective, costly and would distract from arriving at more comprehensive solutions […]